Skip to content

Clinical trials

Breast Carcinoma In Situ trials

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Breast Carcinoma In Situ Clear all

189 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20003
20012
20026
20037
20046
200511
20067
200710
20088
20095
20105
20115
20124
20136
20143
20158
20167
20177
20189
20196
20208
202113
20227
20239
20248
20257
20263

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed107
Recruiting23
Active, not recruiting18
Terminated17
Unknown status11
Withdrawn8
Suspended3
Not yet recruiting1
Enrolling by invitation1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
Mayo Clinic14
National Cancer Institute (NCI)11
Ohio State University Comprehensive Cancer Center11
Alliance for Clinical Trials in Oncology7
Jonsson Comprehensive Cancer Center6
City of Hope Medical Center5
SWOG Cancer Research Network5
M.D. Anderson Cancer Center4
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins4
Wake Forest University Health Sciences4

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Breast Carcinoma In Situ189
Breast Neoplasms142
Carcinoma, Intraductal, Noninfiltrating91
Carcinoma, Lobular14
Carcinoma, Ductal, Breast12
Hot Flashes10
Breast Neoplasms, Male7
Fatigue5
Inflammatory Breast Neoplasms5
Pain5

Trials

Showing 26 to 50 of 189. Each trial links to its page on Pharma Observatory.

89 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.